tirzepatide february 2025 GLP-1 RA prescription trends: January 2018 – June tirzepatide february 2025 Eli Lily

Inayat Shah, Haroon Badshah, and Ehtesham Ehtesham provided critical discussion in the manuscript

In SUSTAIN 6, subjects with T2D at high CV risk treated with semaglutide had a 26% lower risk of the primary composite outcome of first MACE (death from CV causes, nonfatal MI, or nonfatal stroke) vs those receiving placebo over 2 years (p = 0.02 for superiority [post hoc]) [12]

Some states cover GLP-1 medications for diabetes but not weight loss, while others have implemented strict utilization management programs requiring extensive documentation before approval

As they heal, they may turn brown, green or yellow

Chaperone-dependent and chaperone-independent functions of carboxylate clamp tetratricopeptide repeat (CC-TPR) proteins